Pharmaceuticals

Dr Reddys Laboratories

Dr Reddys Laboratories released FY2026 Annual Earnings on May 12 During-Market (EST), actual revenue USD 3.75 B (forecast USD 3.637 B), actual EPS USD 0.574 (forecast USD 0.613)

Dr Reddy's Laboratories released FY2026 Q4 earnings on May 12 During-Market EST, actual revenue USD 796.37 M (forecast USD 859.93 M), actual EPS USD 0.0279 (forecast USD 0.608)

Dr. Reddy's to Launch Semaglutide in Canada and India

FactSet Downgrades RDY-US EPS Estimate for 2026

Dr Reddys Laboratories to release FY2026 Q4 earnings on May 12 During-Market EST, forecast revenue USD 864.91 M, EPS USD 0.608

Dr. Reddy's Labs Gets Approval For Semaglutide Injection From Health Canada

Dr Reddy's Enters Hormone Replacement Therapy Field

Dr Reddys Laboratories released FY2026 Q3 earnings on January 21 During-Market (EST), actual revenue USD 971.96 M (forecast USD 941.33 M), actual EPS USD 0.1617

Dr Reddys Laboratories released FY2026 9 Months Earnings on January 21 During-Market EST, with actual revenue of USD 2.964 B and EPS of USD 0.5551

Dr. Reddy's to Launch Semaglutide in India and Gradually Expand Globally

Dr Reddys Laboratories to Release FY2026 Q3 Earnings on January 21 During Market Hours (EST), Forecast Revenue USD 940.9 M

Dr Reddys Laboratories released FY2026 Semi-Annual earnings on October 24 During-Market (EST), actual revenue USD 1.992 B, actual EPS USD 0.3934

Dr Reddys Laboratories released FY2026 Q2 earnings on October 24 During-Market (EST), actual revenue USD 992.54 M (forecast USD 975.96 M), actual EPS USD 0.1944

Dr Reddy's Laboratories to Release FY2026 Q2 Earnings on October 24 During Market Hours (EST), Forecast Revenue USD 978.55 M

Dr Reddys Laboratories released FY2026 Q1 earnings on July 23 During-Market EST, actual revenue USD 999.26 M (forecast USD 1.013 B), actual EPS USD 0.199

Dr Reddy's Laboratories to release FY2026 Q1 earnings on July 23, 2025, during market hours EST, with forecast revenue of USD 1.013 B

Rhumbline Advisers Reduces Holdings in Dr. Reddy's Laboratories

HSBC Upgrades Dr Reddy's Stock Rating to Buy

HSBC Upgrades WuXi Biologics Rating to 'Buy'

FactSet Raises 2026 EPS Forecast for Dr. Reddy's ADR

InMed Pharmaceuticals

AMPLITECH GROUP INC. USD0.001 S/R 20/11/26 SER B

Amesite

CN Energy

AMPLITECH GROUP INC. COM USD0.001 (S/R 18/07/2026)

NextNRG

Meiwu Tech

Generation Income Properties

MetaVia

OceanPal

Dr Reddy's CEO Erez Israeli highlights the company's strategy to grow in the biosimilars and semaglutide markets, anticipating that biosimilars could surpass generics in the US by the early 2030s. The company aims to leverage its early market entry, scientific capabilities, and global access to navigate pricing pressures and expand its North American portfolio beyond traditional generics. With a focus on oncology and consumer health, Dr Reddy's is poised for significant growth in these segments.

Business Standard

Novo Nordisk AS

Biosimilars could surpass generics in US mkt by early 2030s: Dr Reddy's CEO

Dr. Reddy's Laboratories has launched its generic Semaglutide Injection in Canada, enhancing its GLP-1 portfolio and commitment to affordable diabetes treatments. This positions the company among the first to introduce this product in Canada after receiving Health Canada approval. Despite this positive development, the broader market is facing challenges, with major indices declining. Dr. Reddy's shares are currently trading above the 20-day SMA, indicating short-term bullish sentiment, but below longer-term SMAs, suggesting potential resistance.

benzinga_article

NASDAQ Composite Index

S&P 500

Goldman Sachs

Morgan Stanley

JPMorgan Chase

GS Hldg R

MORGAN STANLEY DEP SHS EA REP 1/1000 SHS NON CUM PFD O

MORGAN STANLEY DEP SHS REPSTG 1/1000TH PFD SER Q

MORGAN STANLEY DEP SHS REPS 1/1000 7.125% PFD E

MORGAN STANLEY NON-CUM DEP SH REP 1/1000 PFD SER I

MORGAN STANLEY 4.875 DEP SHS REP 1/1000 NCUM PFD SR L

MORGAN STANLEY 6.5%DEP SHS REPSTG 1/1000 NON CUM SER P

MORGAN STANLEY DEP SHS REPS 1/1000 PFD SER 'A'

MORGAN STANLEY DEP SHS REPR 1/1000TH INT PFD SER 'F' FX

MORGAN STANLEY DEP SHS REP 1/1000 NON-CUM PFD STK SER K

JPMORGAN CHASE & CO. 4.20% DEP SHS REPSTG 1/400TH PFD SER MM

JPMORGAN CHASE & CO. 6%NON CUM DEP SHS REP 1/400TH PFD SER EE

JPMORGAN CHASE & CO. DEP REP 1/400TH (5.75% NON CUM PFD DD)

JPMORGAN CHASE & CO. 4.625% DEP SH RE 1/400TH INT NO CU PF LL

JPMorgan Chase & Co.

JPMORGAN CHASE & CO. 4.55% DEP SHS REPSTG 1/400TH PFD SER JJ

JPMORGAN CHASE & CO. 4.75 DEP SHS REP 1/400 NCUM PFD SR GG

Dr. Reddy's Launches Generic Semaglutide In Canada, Expands GLP-1 Push

Dr Reddy's Laboratories has launched its generic Semaglutide injection for type 2 diabetes in Canada, becoming one of the first companies to do so after receiving Health Canada's Notice of Compliance. The injection is available in 2 mg and 4 mg pre-filled pens, designed for once-weekly use. CEO Erez Israeli emphasized the company's commitment to providing high-quality GLP-1 therapies and expanding access in global markets.

Dr Reddy's Laboratories launches generic Semaglutide injection in Canada

Dr. Reddy's Laboratories reported a resilient FY 2026 performance with record annual revenue despite challenges from lower lenalidomide sales and one-time charges. CFO M.V. Narasimham noted double-digit growth in the base business, while adjusted profit before tax for Q4 was INR 994 crores. The company anticipates margin improvements in FY 2027, supported by cost efficiencies and new product launches. CEO Erez Israeli highlighted semaglutide and abatacept as key pipeline assets, with significant market expectations for semaglutide in Canada and the U.S. FDA's acceptance of the biosimilar candidate for abatacept.

Market Beat

Teva Pharmaceutical Industries

Immutep Ltd

Immutep

GlaxoSmithKline plc

GSK plc Sponsored ADR

Dr. Reddy's Laboratories Q4 Earnings Call Highlights

Dr. Reddy’s is focusing on India as a growth engine, achieving a turnaround in its domestic business with a 20% year-on-year growth in Q4FY26. Contributing Rs.6,200 crore to FY26 revenue, the company is enhancing its portfolio and productivity while investing in new products and commercial strategies. Despite challenges in chronic therapies, Dr. Reddy’s aims to expand this segment through organic and inorganic growth. The company has improved its market ranking from 10th to 9th in the Indian pharmaceutical market, though it remains cautious about competitive pressures.

Money Control

IQVIA

Dr Reddy’s revives India business in FY26 with portfolio, productivity reset

Dr. Reddy's Laboratories Ltd's average stock price target has been reduced from $14.34 to $13.78, indicating an 11% potential upside based on the May 12 closing price. The consensus rating remains a 'Hold' among 30 analysts, with 8 Buy, 10 Hold, and 12 Sell recommendations. Forecasts for the stock range from $10.87 to $18.36 per share.

TradingView

Dr. Reddy's Laboratories Ltd Stock 12‑Month Price Target Cut to $13.78, Implies 11% Upside